PHARMING GROUP NV (PHGN.DE) Stock Price & Overview
FRA:PHGN • NL0010391025
The current stock price of PHGN.DE is 1.326 EUR. Today PHGN.DE is down by -4.47%. In the past month the price increased by 0.23%.
PHGN.DE Key Statistics
- Market Cap
- 92.381M
- P/E
- N/A
- Fwd P/E
- 38.71
- EPS (TTM)
- N/A
- Dividend Yield
- N/A
PHGN.DE Stock Performance
PHGN.DE Stock Chart
PHGN.DE Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to PHGN.DE.
PHGN.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to PHGN.DE. Both the profitability and the financial health of PHGN.DE get a neutral evaluation. Nothing too spectacular is happening here.
PHGN.DE Earnings
On November 6, 2025 PHGN.DE reported an EPS of 0.01 and a revenue of 97.30M. The company beat EPS expectations (1070.87% surprise) and beat revenue expectations (1.11% surprise).
PHGN.DE Forecast & Estimates
14 analysts have analysed PHGN.DE and the average price target is 2.19 EUR. This implies a price increase of 65.38% is expected in the next year compared to the current price of 1.326.
For the next year, analysts expect an EPS growth of 68.53% and a revenue growth 29.06% for PHGN.DE
PHGN.DE Groups
Sector & Classification
PHGN.DE Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 0.11% | ||
| ROA | 0.08% | ||
| ROE | 0.14% | ||
| Debt/Equity | 0.46 |
PHGN.DE Ownership
PHGN.DE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1AE | ARGENX SE | 25.5 | 38.133B | ||
| ARGX | ARGENX SE | 25.58 | 38.12B | ||
| 22UA | BIONTECH SE-ADR | N/A | 18.515B | ||
| ABVX | ABIVAX SA | N/A | 8.129B | ||
| 2X1 | ABIVAX SA | N/A | 8.097B | ||
| GXE | GALAPAGOS NV | N/A | 1.831B | ||
| GLPG | GALAPAGOS NV | N/A | 1.827B | ||
| NANO | NANOBIOTIX | N/A | 1.328B | ||
| IVA | INVENTIVA SA | N/A | 1.098B | ||
| 6IV | INVENTIVA SA | N/A | 1.098B | ||
| PHIL | PHILOGEN SPA | 18.09 | 663.748M | ||
| XUP | GENFIT | N/A | 468.027M | ||
| GNFT | GENFIT | 854.9 | 435.275M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About PHGN.DE
Company Profile
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company is headquartered in Leiden, Zuid-Holland and currently employs 426 full-time employees. The firm is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The firm's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
Company Info
IPO: 1998-07-02
PHARMING GROUP NV
Darwinweg 24
Leiden ZUID-HOLLAND NL
Employees: 404
Phone: 31715247400
PHARMING GROUP NV / PHGN.DE FAQ
What does PHGN do?
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company is headquartered in Leiden, Zuid-Holland and currently employs 426 full-time employees. The firm is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The firm's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
Can you provide the latest stock price for PHARMING GROUP NV?
The current stock price of PHGN.DE is 1.326 EUR. The price decreased by -4.47% in the last trading session.
Does PHGN stock pay dividends?
PHGN.DE does not pay a dividend.
What is the ChartMill rating of PHARMING GROUP NV stock?
PHGN.DE has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What is PHARMING GROUP NV worth?
PHARMING GROUP NV (PHGN.DE) has a market capitalization of 92.38M EUR. This makes PHGN.DE a Micro Cap stock.
Can you provide the upcoming earnings date for PHARMING GROUP NV?
PHARMING GROUP NV (PHGN.DE) will report earnings on 2026-03-12, before the market open.
What is the ownership structure of PHARMING GROUP NV (PHGN.DE)?
You can find the ownership structure of PHARMING GROUP NV (PHGN.DE) on the Ownership tab.